Opdivo in Head and Neck Cancer: Results from the CheckMate 141 Trial
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
At the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, Dr. Robert L. Ferris from the University of Pittsburgh presented the results of the CheckMate 141 Phase 3 clinical trial. This study investigated the efficacy of Opdivo (Nivolumab) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who had progressed on platinum-based chemotherapy.
Study Design: CheckMate 141 Trial
The trial randomized 361 patients in a 2:1 ratio:
- Opdivo Group (N=240): Nivolumab 3 mg/kg every two weeks.
- Investigator’s Choice Group (N=121): Standard chemotherapy (Methotrexate, Docetaxel, or Cetuximab).
Key Survival Results
The trial demonstrated a significant survival benefit for patients receiving Opdivo:
- One-Year Survival Rate: 36.0% for the Opdivo group vs. 16.6% for the investigator's choice group—effectively doubling the survival rate at one year.
- Median Overall Survival: 7.5 months for Opdivo vs. 5.1 months for standard therapy.
The benefit of Opdivo was observed across different PD-L1 expression levels, though patients with higher PD-L1 expression showed even greater survival improvements.
Safety and Tolerability
Opdivo also proved to be better tolerated than standard chemotherapy:
- Adverse Event Rate: 58.9% in the Opdivo group vs. 77.5% in the investigator's choice group.
- Quality of Life: Patients in the Opdivo group reported stable or improved physical, social, and emotional functioning, whereas those in the chemotherapy group experienced declines.
Conclusion
The CheckMate 141 trial established Opdivo as a new standard of care for patients with platinum-refractory recurrent or metastatic head and neck cancer, offering superior survival and better quality of life compared to conventional chemotherapy.
Source: ASCO 2016 - CheckMate 141 Abstract #6009
#HeadAndNeckCancer #SCCHN #Opdivo #Nivolumab #CheckMate141 #ASCO2016 #Immunotherapy
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5